Which has higher earnings & valuation, DERM or IVA?

Journey Medical has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Journey Medical $61.86M 2.97 -$11.43M -$0.22 N/A Inventiva $4.48M 159.85 -$400.67M N/A N/A

Does the media favor DERM or IVA?

In the previous week, Inventiva had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.70 beat Inventiva's score of 0.24 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, GLAS or DERM?

Glass House Brands has higher earnings, but lower revenue than Journey Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands N/A N/A N/A N/A N/A Journey Medical $61.86M 2.97 -$11.43M -$0.22 N/A

Does the media refer more to DERM or GYRE?

In the previous week, Journey Medical and Journey Medical both had 2 articles in the media. Journey Medical's average media sentiment score of 0.70 beat Gyre Therapeutics' score of 0.42 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DERM or ACHV?

In the previous week, Achieve Life Sciences had 3 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Achieve Life Sciences and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.70 beat Achieve Life Sciences' score of 0.14 indicating that Journey Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Achieve Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Journey Medical (DERM) Competitors

$6.50 -0.75 (-10.34%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$6.42 -0.08 (-1.23%)

As of 05:58 AM Eastern

Compare

DERM vs. FBIO, IVA, GLAS, GYRE, and ACHV

Should you buy Journey Medical stock or one of its competitors? Journey Medical's main competitors and comparable companies include Fortress Biotech (FBIO), Inventiva (IVA), Glass House Brands (GLAS), Gyre Therapeutics (GYRE), and Achieve Life Sciences (ACHV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Journey Medical compare to Fortress Biotech?

Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Fortress Biotech has a net margin of 163.32% compared to Journey Medical's net margin of -8.95%. Fortress Biotech's return on equity of 83.47% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Fortress Biotech	163.32%	83.47%	42.98%

Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Journey Medical presently has a consensus target price of $14.00, suggesting a potential upside of 115.38%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 626.50%. Given Fortress Biotech's higher probable upside, analysts clearly believe Fortress Biotech is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 14.5% of Journey Medical shares are held by company insiders. Comparatively, 28.5% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Fortress Biotech has higher revenue and earnings than Journey Medical. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.97	-$11.43M	-$0.22	N/A
Fortress Biotech	$63.26M	1.23	$6.82M	$2.64	0.89

In the previous week, Journey Medical had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for Fortress Biotech. Journey Medical's average media sentiment score of 0.70 beat Fortress Biotech's score of 0.00 indicating that Journey Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Journey Medical	Positive
Fortress Biotech	Neutral

Summary

Fortress Biotech beats Journey Medical on 11 of the 14 factors compared between the two stocks.

How does Journey Medical compare to Inventiva?

Journey Medical (NASDAQ:DERM) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, profitability, media sentiment, earnings and dividends.

In the previous week, Inventiva had 1 more articles in the media than Journey Medical. MarketBeat recorded 3 mentions for Inventiva and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.70 beat Inventiva's score of 0.24 indicating that Journey Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inventiva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Journey Medical presently has a consensus target price of $14.00, suggesting a potential upside of 115.38%. Inventiva has a consensus target price of $15.75, suggesting a potential upside of 356.52%. Given Inventiva's stronger consensus rating and higher probable upside, analysts plainly believe Inventiva is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Inventiva has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market.

Inventiva has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Inventiva's return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Inventiva	N/A	N/A	N/A

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Journey Medical has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.97	-$11.43M	-$0.22	N/A
Inventiva	$4.48M	159.85	-$400.67M	N/A	N/A

Summary

Inventiva beats Journey Medical on 11 of the 15 factors compared between the two stocks.

How does Journey Medical compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Glass House Brands has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Glass House Brands' return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Journey Medical	-8.95%	-20.23%	-6.60%

In the previous week, Journey Medical had 2 more articles in the media than Glass House Brands. MarketBeat recorded 2 mentions for Journey Medical and 0 mentions for Glass House Brands. Journey Medical's average media sentiment score of 0.70 beat Glass House Brands' score of 0.00 indicating that Journey Medical is being referred to more favorably in the news media.

Company	Overall Sentiment
Glass House Brands	Neutral
Journey Medical	Positive

Glass House Brands has higher earnings, but lower revenue than Journey Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	N/A	N/A	N/A	N/A	N/A
Journey Medical	$61.86M	2.97	-$11.43M	-$0.22	N/A

Glass House Brands currently has a consensus price target of $16.00, indicating a potential upside of 104.66%. Journey Medical has a consensus price target of $14.00, indicating a potential upside of 115.38%. Given Journey Medical's stronger consensus rating and higher possible upside, analysts clearly believe Journey Medical is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

7.3% of Journey Medical shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Journey Medical beats Glass House Brands on 8 of the 11 factors compared between the two stocks.

How does Journey Medical compare to Gyre Therapeutics?

Journey Medical (NASDAQ:DERM) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Journey Medical presently has a consensus price target of $14.00, indicating a potential upside of 115.38%. Gyre Therapeutics has a consensus price target of $16.00, indicating a potential upside of 116.22%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Gyre Therapeutics has higher revenue and earnings than Journey Medical. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Journey Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.97	-$11.43M	-$0.22	N/A
Gyre Therapeutics	$116.59M	7.08	$5.03M	-$0.21	N/A

Journey Medical has a net margin of -8.95% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

Journey Medical has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

In the previous week, Journey Medical and Journey Medical both had 2 articles in the media. Journey Medical's average media sentiment score of 0.70 beat Gyre Therapeutics' score of 0.42 indicating that Journey Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gyre Therapeutics beats Journey Medical on 9 of the 15 factors compared between the two stocks.

How does Journey Medical compare to Achieve Life Sciences?

Journey Medical (NASDAQ:DERM) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

Achieve Life Sciences has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Achieve Life Sciences	N/A	-511.12%	-82.35%

Journey Medical has higher revenue and earnings than Achieve Life Sciences. Journey Medical is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.97	-$11.43M	-$0.22	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Journey Medical presently has a consensus price target of $14.00, indicating a potential upside of 115.38%. Achieve Life Sciences has a consensus price target of $15.00, indicating a potential upside of 91.57%. Given Journey Medical's higher possible upside, research analysts plainly believe Journey Medical is more favorable than Achieve Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Achieve Life Sciences had 3 more articles in the media than Journey Medical. MarketBeat recorded 5 mentions for Achieve Life Sciences and 2 mentions for Journey Medical. Journey Medical's average media sentiment score of 0.70 beat Achieve Life Sciences' score of 0.14 indicating that Journey Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Achieve Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Journey Medical has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market.

Summary

Journey Medical and Achieve Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DERM vs. The Competition

Export

Metric	Journey Medical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$204.63M	$12.60B	$7.31B	$13.29B
Dividend Yield	N/A	2.63%	2.52%	12.57%
P/E Ratio	-29.55	792.28	274.08	25.69
Price / Sales	2.97	862.22	638.21	78.99
Price / Cash	N/A	88.64	77.80	52.76
Price / Book	6.77	10.59	10.47	6.32
Net Income	-$11.43M	$2.81B	$3.49B	$359.73M
7 Day Performance	-11.68%	-0.11%	-0.67%	0.17%
1 Month Performance	-17.83%	-1.34%	-3.17%	-3.27%
1 Year Performance	-9.72%	2.86%	15.14%	5.58%

Journey Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DERM Journey Medical	1.6856 of 5 stars	$6.50 -10.3%	$14.00 +115.4%	-13.4%	$204.63M	$61.86M	N/A	58	High Trading Volume
FBIO Fortress Biotech	1.8942 of 5 stars	$2.49 -1.6%	$17.00 +582.7%	-35.9%	$84.38M	$68.47M	0.94	170
IVA Inventiva	2.6127 of 5 stars	$3.86 -0.5%	$15.75 +308.0%	-39.2%	$805.91M	$5.07M	N/A	73	Upcoming Earnings High Trading Volume
GLAS Glass House Brands	2.7043 of 5 stars	$8.01 -1.1%	$16.00 +99.7%	N/A	$759.78M	N/A	N/A	357
GYRE Gyre Therapeutics	1.7785 of 5 stars	$6.69 flat	$16.00 +139.2%	+1.4%	$746M	$116.59M	N/A	618	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DERM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Journey Medical (DERM) Competitors

DERM vs. FBIO, IVA, GLAS, GYRE, and ACHV

How does Journey Medical compare to Fortress Biotech?

Summary

How does Journey Medical compare to Inventiva?

Summary

How does Journey Medical compare to Glass House Brands?

Summary

How does Journey Medical compare to Gyre Therapeutics?

Summary

How does Journey Medical compare to Achieve Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Journey Medical (DERM) Competitors

DERM vs. FBIO, IVA, GLAS, GYRE, and ACHV

How does Journey Medical compare to Fortress Biotech?

Is DERM or FBIO more profitable?

Which has more volatility and risk, DERM or FBIO?

Do analysts recommend DERM or FBIO?

Do institutionals & insiders hold more shares of DERM or FBIO?

Which has stronger earnings & valuation, DERM or FBIO?

Does the media prefer DERM or FBIO?

Summary

How does Journey Medical compare to Inventiva?

Does the media favor DERM or IVA?

Do analysts recommend DERM or IVA?

Which has more volatility & risk, DERM or IVA?

Is DERM or IVA more profitable?

Do insiders and institutionals have more ownership in DERM or IVA?

Which has higher earnings & valuation, DERM or IVA?

Summary

How does Journey Medical compare to Glass House Brands?

Is GLAS or DERM more profitable?

Does the media refer more to GLAS or DERM?

Which has higher earnings and valuation, GLAS or DERM?

Do analysts prefer GLAS or DERM?

Do institutionals & insiders believe in GLAS or DERM?

Summary

How does Journey Medical compare to Gyre Therapeutics?

Do insiders & institutionals believe in DERM or GYRE?

Do analysts prefer DERM or GYRE?

Which has better valuation & earnings, DERM or GYRE?

Is DERM or GYRE more profitable?

Which has more risk and volatility, DERM or GYRE?

Does the media refer more to DERM or GYRE?

Summary

How does Journey Medical compare to Achieve Life Sciences?

Is DERM or ACHV more profitable?

Which has preferable earnings and valuation, DERM or ACHV?

Do institutionals and insiders believe in DERM or ACHV?

Do analysts prefer DERM or ACHV?

Does the media prefer DERM or ACHV?

Which has more risk & volatility, DERM or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DERM vs. The Competition

Journey Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools